Podcasts about biochemical sciences

In this episode, I interviewed Dr. Antentor Hinton Jr. Per his biosketch on his lab website, he is a tenure-track Assistant Professor in the Department of Molecular Physiology and Biophysics in the Vanderbilt School of Medicine Basic Sciences at Vanderbilt University and a member of the Vanderbilt Diabetes Research and Training Center and the Ernest E. Just Early Career Investigator. Dr. Hinton's laboratory has a strong commitment to diversity. Dr. Hinton has published 8 STEM education papers and 32 diversity, equity, inclusion, mentoring, and career development commentaries. Dr. Hinton is currently a national leader on matters related to diversity, equity, inclusion and mentoring. Some of Dr Hinton's publications include Cell, 2023 (First DEI cover article), Cell, 2022, Cell, 2020, EMBO, 2020 (a), EMBO 2020 (b) Nature Biotechnology, 2020, Trends in Cancer, 2021, Trends in Biochemical Sciences, 2021, Trends in Biochemical Sciences 2022, Cell Reports Medicine, 2021 (Shared 2nd Anniversary Cover), Cell Reports Medicine, 2022, Trends in Immunology 2022, Trends in Cell Biology 2022 (a), Trends in Cell Biology (b), Trends in Biochemical Sciences, 2022 (First DEI/career development cover article for a scientific journal), Trends in Plant Sciences, 2022 (Second DEI/Career development cover article for a scientific journal, Trends in Parasitology, 2022 (Third DEI/Career development cover article for a scientific journal), Trends in Chemistry, 2023 (Fourth DEI/Career Development cover article for a scientific journal) and Trends in Pharmacological Sciences, 2022 (First mentoring cover article for a scientific journal). These pieces are constructive and heavily use the literature to make recommended suggestions. --- Send in a voice message: https://podcasters.spotify.com/pod/show/fromwheredoesitstem/message

David Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG.Previously, David started and led Novartis' Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto.David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I and Senti Biosciences, Inc.w/ Special Guest Host: Brian Fiske - Co-Founder & CSO @ Mythic TherapeuticsBrian Fiske co-founded Mythic in 2017 & currently serves as Mythic's Chief Scientific Officer. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he also co-founded KSQ Therapeutics. During his time at Flagship, Brian successfully led R&D teams to key milestones, recruited 25+ FTEs across all levels of seniority, and raised $34M across multiple rounds of financing. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30.Prior to Flagship, Brian completed his PhD in biology in Matt Vander Heiden's lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs that include two approved drugs. He holds an AB summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

#neuroscience #healthcare #health Dr. Isaac Chen is an Assistant Professor in the Department of Neurosurgery at the University of Pennsylvania. He is also the Section Chief of Neurosurgery at the Philadelphia Veterans Affairs Medical Center. He obtained his undergraduate degree in Biochemical Sciences from Harvard University. Subsequently, he completed medical school and neurosurgical residency at the University of Pennsylvania. His clinical interests include functional neurosurgery, epilepsy surgery, traumatic brain injury, and brain tumors (especially those in eloquent cortex). As a surgeon and a scientist, Dr. Chen's primary focus is the preservation and restoration of brain function. The Chen Laboratory works to "develop novel methods for restoring the function of the brain after it has been damaged by combining aspects of stem cell biology, neural tissue engineering, and neural interface technologies. Prof Chen is the Member of Center for Brain Injury and Repair Institute of Regenerative Medicine Institute for Translational Medicine and Therapeutics Center for Neuroengineering and Therapeutics. Dr Chen & researchers at the University of Pennsylvania have been working on Brain Organoids & have found that human-derived brain organoids can integrate into the visual cortex of rat brains. After three months, the organoids demonstrate electrical responses to visual stimuli. The term “organoid” encompasses 3D cell culture systems that can be derived from stem cells, tumors, tissue explants, stem cells or other progenitor cells. Organoids “self-organize” under specific, controlled conditions, resembling the anatomy, physiology and complexity of organs or other body structures in a dish. https://www.med.upenn.edu/apps/faculty/index.php/g275/p35031https://www.linkedin.com/in/isaac-chen-3051035 Connect & Follow us at: https://in.linkedin.com/in/eddieavil https://in.linkedin.com/company/change-transform-india https://www.facebook.com/changetransformindia/ https://twitter.com/intothechange https://www.instagram.com/changetransformindia/ Listen to the Audio Podcast at: https://anchor.fm/transform-impossible https://podcasts.apple.com/us/podcast/change-i-m-possibleid1497201007?uo=4 https://open.spotify.com/show/56IZXdzH7M0OZUIZDb5mUZ https://www.breaker.audio/change-i-m-possible https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8xMjg4YzRmMC9wb2RjYXN0L3Jzcw Dont Forget to Subscribe www.youtube.com/ctipodcast

Dr. Moupali Das, MD, MPH, is Executive Director, HIV Clinical Research, in the Virology Therapeutic Area, at Gilead Sciences ( https://www.gilead.com/ ) , where she leads the pre-exposure prophylaxis (PrEP) clinical drug development program, including evaluating the safety and efficacy of a long-acting, twice yearly, subcutaneous injection being studied for HIV prevention. Her responsibilities also include expanding the populations who may benefit from PrEP. Dr. Das has led high-performing teams in academic medicine, public health, implementation science, and cross-functionally in drug development. She has successfully helped develop, implement, and evaluate how to better test, link to care, increase virologic suppression, and improve quality of life for people with HIV, and to prevent HIV in those who may benefit from PrEP. During the COVID19 pandemic, Dr. Das assisted her colleagues in the COVID-19 treatment program, leading the evaluation of a COVID-19 treatment for use in pregnant women and children from the compassionate use program. After completing her undergraduate degree in Biochemical Sciences at Harvard College, medical school and internal medicine residency training at Columbia University and New York Presbyterian Hospital, Dr. Das came to University of California, San Francisco (UCSF) for fellowship training in Infectious Diseases and to University of California, Berkeley for her MPH in Epidemiology. She cared for HIV patients at San Francisco General's storied Ward 86 clinic and attended on the inpatient ID Consult Service. She is recognized internally and externally for her expertise in epidemiology, public health, advocacy, and community engagement. Prior to joining Gilead, Dr. Das developed a novel population-based indicator, community viral load (CVL), to evaluate the impact of treatment as prevention. Her CVL research was the basis for using viral suppression to evaluate the effectiveness of President Barack Obama's National HIV/AIDS Strategy. She also served on the Institute of Medicine Committee on Data Systems for Monitoring HIV/AIDS care. Dr. Das has authored over 60 manuscripts, presented at scientific conferences, policy forums, and for community and advocacy organizations. Her publications have been highly cited and garnered significant press coverage including in The New York Times and Nature. Dr. Das appears in her personal capacity and any views expressed are her own. Support the show

Mr. Chavez said, “The creative energy the Sixth Street team brings to everything they do gives me tremendous confidence in what we are capable of building together. In addition to the development of our engineering environment, I look forward to contributing my passion for converging the life sciences and software as we explore more opportunities to work with companies delivering solutions for our most pressing health challenges.” Mr. Chavez currently serves as President of the Board of Overseers of Harvard University. He also serves on the fiduciary or advisory boards of Cambrian, Earli, Grupo Santander, the Los Angeles Philharmonic, Recursion Pharma, Stanford Medicine, and the Stanford Center on Longevity. He is among the most senior Latinos in finance, as well as among the most senior openly gay executives. Prior to joining Sixth Street, Mr. Chavez served in a variety of senior roles at Goldman Sachs, including Chief Information Officer, Chief Financial Officer, and global co-head of the firm's Securities Division. Mr. Chavez was also a partner and member of the Goldman Sachs Management Committee. Mr. Chavez was one of the first developers of SecDB, an early platform that transformed the trading business into a software business. He retired from the firm in 2019. Prior to joining Goldman Sachs, Mr. Chavez was the CEO and co-founder of Kiodex, and Chief Technology Officer and co-founder of Quorum Software Systems. He holds an A.B. magna cum laude in Biochemical Sciences and an S.M. in Computer Science from Harvard, and a Ph.D. in Medical Information Sciences from Stanford. About Sixth Street Sixth Street is a global investment firm with over $50 billion in assets under management and committed capital. Sixth Street operates nine diversified, collaborative investment platforms: TAO, Growth, Specialty Lending, Fundamental Strategies, Infrastructure, Opportunities, Insurance, Agriculture, and Credit Market Strategies. Select current and past representative Sixth Street investments include Airbnb, AvidXchange, Caris Life Sciences, Kyriba, Nektar Therapeutics, Legends, Spotify, and Talcott Resolution. Our long-term oriented, highly flexible capital base and “One Team” cultural philosophy allow us to invest thematically across sectors, geographies, and asset classes. Founded in 2009, Sixth Street has more than 320 team members including over 145 investment professionals operating from nine locations around the world. For more information, visit www.sixthstreet.com or follow us on LinkedIn. --- Support this podcast: https://anchor.fm/toby-usnik/support

Is Medicine influenced by Philosophy? Enjoy this short session with our special guest Dr Ogan Gurel MD, where he introduces us to the Philosophy of Medicine. For further details please visit mini-md.com. Dr Gurel holds an MD (Alpha Omega Alpha) and MPhil (Biochemistry & Molecular Biophysics) from Columbia University. Earning a BA (cum laude in Biochemical Sciences) at Harvard University. In addition to working as a Chief Science Officer, he runs the popular and highly regarded program called Mini-MD (Mini Medical School). Hosted by lawyer and philosopher, Bianca Rose Phillips.

Today's guest John Hall, Ph.D. discusses the Beljanski Foundation and its natural approach to cancer.  John has served as an Executive in the Biotechnology Industry and is currently Vice President for Research and Development at Molecular International Research and Director of Research at The Beljanski Foundation. Dr. Hall was a Graduate Fellow at Princeton University, in the Department of Biochemical Sciences, and he completed his Ph.D. at New York University, in the Department of Biochemistry. In this episode, John Hall explains the nutraceuticals behind the amazing Beljanski product Onkobel-Pro as well as the purified RNA extract, Immunobel-Pro.  The two anti-cancer plant extracts in Onkobel pro were originally developed by Mirko Beljanski as a natural approach to cancer.  They have been shown to help those diagnosed with as well as those who want to prevent cancer.  In addition, listen in to learn about some new and exciting research that the foundation is funding, beneficial to late-stage cancers.

One of the positives during the current pandemic is that both healthcare professionals and consumers have made gains in expanding the possibilities of the health curve, in particular with the use of digital technologies related to therapeutic devices, telehealth, and remote monitoring, however, overall health literacy remains an opportunity and is positioned for even more growth. Today's episode gives listeners unique insights into the world of health with a particular focus on health literacy. This episode's guest is Dr. Ogan Gurel, a Chief Science Officer, founder of The Mini Medical School, Mini-MD, and author of Waves, The Book, which is a story that recounts the adventures of the contemplative and idealistic Tomas, a doctor-turned-entrepreneur who's discovered a new technology with both medical and military applications. His experiences span the executive, marketing, clinical and R&D domains, with sector expertise in medical devices, digital health, medical imaging, and biopharma as well as academic research focused on protein electrodynamics and terahertz medicine. He also serves as a venture partner in addition to several academic appointments. Dr. Gurel holds an MD and MPhil in Biochemistry & Molecular Biophysics from Columbia University as well as a Bachelor of Arts in Biochemical Sciences from Harvard, where he conducted research in molecular dynamics with Martin Karplus, who was awarded the 2013 Nobel Prize in Chemistry. For more details visit TechLink Health @ https://www.techlink.health or connect with Dr. Gurel @ https://www.linkedin.com/in/ogangurel/. This episode was hosted by Justine Reiss. If you're a healthcare practitioner or thought leader and interested in leveraging the TechLink Health platform for telehealth, e-consults, or advisory services, feel free to connect with us by visiting our site or downloading the TechLink Health app. iOS - https://apps.apple.com/app/techlink-health/id1492325493 Google Play - https://play.google.com/store/apps/details?id=millennialtech.techlinkhealth

Dr. Yung Chyung, Chief Medical Officer at Scholar Rock, a clinical-stage biopharmaceutical company discusses the positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). Dr. Yung H. Chyung has served as Chief Medical Officer since February 2016 and leads the clinical development of pipeline candidates and medical affairs. Prior to joining Scholar Rock, Yung served in roles of increasing responsibility at Dyax Corp. (acquired by Shire Plc in January 2016) from 2011 to February 2016, most recently serving as Vice President of Medical Research, where he was responsible for clinical research and medical affairs. From 2010 to 2011, he worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple rare disease programs. Yung earned his MD from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an AB in Biochemical Sciences from Harvard College.

The connection between the brain, body, and mind is the connection between the subunits of our living world. Professor Alan Jasanoff, director of the Center for Neurobiological Engineering at MIT, explored this topic in his book The Biological Mind. Professor Jasanoff obtained his Bachelor's Degree in Biochemical Sciences at Harvard College. After completing his Masters in Chemistry … Continue reading "206: Alan Jasanoff | The Connection Between Brain And Body, And More From “The Biological Mind”" The post 206: Alan Jasanoff | The Connection Between Brain And Body, And More From “The Biological Mind” appeared first on The Armen Show.

Za odkrivanje in zdravljenje raka in drugih bolezni znanstveniki razvijajo vedno nove pristope. Veliko obeta uporaba proteaz, tako za diagnostične namene kot za samo zdravljenje. Gre za zelo raznoliko vrsto encimov, ki razstavljajo beljakovine. Kjer jih je nadpovprečno veliko, poteka vnetje, zato lahko z njihovo pomočjo na neinvaziven način prepoznamo več tisoč različnih bolezni, vključno s številnimi oblikami raka. Slika, ki se ob navzočnosti proteaz izriše o dogajanju v telesu, je tako natančna, da bodo z njihovo pomočjo lahko tumorje tudi učinkoviteje kirurško odstranjevali. Pregled dogajanja na področju je za ugledno znanstveno revijo Trends in Biochemical Sciences s kolegi pripravil prof. ddr. Boris Turk, vodja odseka za biokemijo, molekularno in strukturno biologijo Instituta »Jožef Stefan«. Za samo zdravljenje trdnih tumorjev pa obeta tudi uporaba nanomaterialov, saj so rezultati predkliničnih raziskav so zelo prepričljivi. O tem uspehu so članek objavili v reviji Nano Letters.

Listen NowCurrently, CMS is accepting public comment on a proposed Medicare Shared Savings Program (MSSP), known more commonly as the Accountable Care Organization (ACO) program, rule.  The MSSP, created under the 2010 Affordable Care Act, is Medicare's flagship pay or performance program currently providing care to over 10 million Medicare beneficiaries.  MSSP or ACO performance, or to the extent the program has reduced Medicare spending growth, has been widely debated largely because CMS has failed to evaluate the program  Under this administration the program has come under substantial criticism.  The proposed rule, published this past August 17 in the Federal Register, is this administration's effort to improve the program's performance moreover by reducing the number of years an provider can participate in the program, from six years to two, without taking financial risk or participate in what are termed upside only contracts.  The administration argues absent financial risk providers do not fully engage in practice reforms to reduce spending.  This assumption is also widely debated.  Absent other substantial payment innovations, the success of the MSSP or ACO program is vital to the Medicare program, now forcasted to go bankrupt in 2026. During this 30 minute conversation Mr. Gronniger begins with a a brief overview of Caravan's work, he discusses or explains what success the ACO program has achieved to date and the program's background.  He moves onto discussing numerous elements of the proposed rule including earned shared savings percents, risk adjustment, aspects of financial benchmarking, low and high revenue ACOs, and beneficiary engagement and incentives, among others.     Mr. Tim Gronniger is currently the Senior Vice President of Development and Strategy at Caravan Health.  Previously, he served as Chief of Staff and Director of Delivery System Reform at CMS.  Previous to that, Mr. Gronniger  was Senior Adviser for Health Care Policy for the White House Domestic Policy Council.  Before that he served as senior professional staff to the Ranking Member of the House Committee on Energy and Commerce, Rep. Henry Waxman (D-CA, now retired).  Mr. Gronniger began his career in Washington, D.C. at the Congressional Budget Office where he studied or scored Medicare and Medicaid legislation.  Mr. Gronniger holds a Masters in Public Policy and Health Services Administration from the University of Michigan and a BA in Biochemical Sciences from Harvard. The proposed ACO rule is at: https://www.federalregister.gov/documents/2018/08/17/2018-17101/medicare-program-medicare-shared-savings-program-accountable-care-organizations-pathways-to-successFor information concerning Caravan Health go to: https://caravanhealth.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

In this edition, we learn about the superhighway of nerves that connects the two halves of the human brain with Ilan Gobius, Cell Reports (0:00), why naked mole rats don’t feel pain with Gary Lewin, Cell Reports (8:00), and the prospects for unisex birth control with Polina Lishko, Trends in Biochemical Sciences (14:40).

In this edition, we’ll hear about how some of our immunity genes are passed down from Neanderthals, with Lluis Quintana-Murci, The American Journal of Human Genetics (00: 00), whether chimps trust their friends, with Jan Engelmann, Current Biology (6:25), the 40th anniversary of Trends in Biochemical Sciences, with Nicole Neuman (16:05), and considerations for job-seeking postdocs (24:30). Plus much more!

In this edition, we learn about about how the poison botulinum toxin alters cell functions, with K. Ravi Acharya (00:00) (Trends in Biochemical Sciences), how recording electrical activity from neurons in awake humans, with Rodrigo Quian Quiroga (8:20) (Neuron) and how dynamic changes in genetic material called chromatin control key features of cell function, with Tom Misteli (15:35) (special issue of Trends in Cell Biology). Plus more great research highlights from around Cell Press (25:00). 

Explore the Provocative Findings of IV Chelation Therapy in Post Heart Attack Patients Obtained from the TACT Trial (Trial to Assess Chelation Therapy) Kirk Hamilton interviews Gervasio A. Lamas, MD Chairman of Medicine at Mount Sinai Medical Center and Chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center. He received his B.A. in Biochemical Sciences cum laude from Harvard College and his M.D. with honors (AOA) from New York University. He completed his Internship and Residency at the Brigham and Women's Hospital of Harvard Medical School, where he later served as Assistant Professor of Medicine. His interests include the treatment and prevention of cardiovascular disease. During the last decade, he has enrolled thousands of patients in more than a dozen U.S. and international trials in order to improve cardiac care and prevent death and disability from heart disease. He presently serves as Co-Chairman for the Occluded Artery Trial (OAT), and Study Chair for the Trial to Assess Chelation Therapy (TACT), a $30 million trial sponsored by the National Institutes of Health. He has authored over 300 scientific publications, and maintains an active clinical practice in Miami Beach and Key Biscayne. He is the co-author of a recent paper published in JAMA, "Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial InfarctionThe TACT Randomized Trial." Download or Open: